Human heavy chain antibody genes elicited in Thai dengue patients during DENV2 secondary infection.

Human heavy chain antibody genes elicited in Thai dengue patients during DENV2 secondary infection. Jpn J Infect Dis. 2019 Nov 29;: Authors: Thammasonthijarern N, Puangmanee W, Sriburin P, Injampa S, Chatchen S, Phumirattanaprapin W, Pipattanaboon C, Ramasoota P, Pitaksajjakul P Abstract Dengue is one of the most serious mosquito-borne viral diseases occurring in humans. From their complexity of 4 serotypes, the ideal vaccine for dengue should be able to stimulate cross-neutralizing antibodies. Recently, genetic-based immune response have been studied for guiding of vaccine design for several viral pathogens. Despite a recent approval of dengue vaccine, the information of genetics-based immune response against dengue virus (DENV) are still limited. Consequently, we aimed to determine the profiles of immunoglobulin heavy chain gene from DENV2 infected patients. The immunoglobulin heavy chain variable region genes (IGHV) were amplified from peripheral blood mononuclear cells of DENV2 secondary infected patients over the acute, convalescence and recovery phases. Antibody heavy chain genes were sequenced by next-generation sequencing (NGS), and analyzed to identify correlations with neutralizing and enhancing activities of the serum samples. IGHV1-69, 3-23, and 3-30 were frequently discovered in our Thai DENV2 infected patients. Our findings provided the new data on the human B cell response during secondary DENV2 infections in Thai dengue patients that prov...
Source: Japanese Journal of Infectious Diseases - Category: Infectious Diseases Authors: Tags: Jpn J Infect Dis Source Type: research

Related Links:

Researchers have reported that a new vaccine against the dengue virus protected children and adolescents in a phase 3 trial conducted in Asia and Latin America.
Source: JAMA - Category: General Medicine Source Type: research
Conclusions/SignificanceAchieving high uptake and compliance with PPT in populations most at risk of adverse outcomes from Zika infection requires engaging key users in open dialogue to identify and address any practical issues regarding PPT use, and concerns over safety. The findings presented here suggest that educational campaigns should strongly emphasize the risks associated with Zika during pregnancy, and discuss safety profiles of approved synthetic repellents and the availability of EPA-approved plant-based repellents. In addition, the economic and political context should be a major consideration when evaluating p...
Source: PLoS Neglected Tropical Diseases - Category: Tropical Medicine Authors: Source Type: research
by Anne L. Wilson, Orin Courtenay, Louise A. Kelly-Hope, Thomas W. Scott, Willem Takken, Steve J. Torr, Steve W. Lindsay Vector-borne diseases (VBDs) such as malaria, dengue, and leishmaniasis exert a huge burden of morbidity and mortality worldwide, particularly affecting the poorest of the poor. The principal method by which these diseases are controlled is through vector control, which has a long and distinguishe d history. Vector control, to a greater extent than drugs or vaccines, has been responsible for shrinking the map of many VBDs. Here, we describe the history of vector control programmes worldwide from the lat...
Source: PLoS Neglected Tropical Diseases - Category: Tropical Medicine Authors: Source Type: research
Abstract In this paper we introduce a single serotype transmission model, including an age-dependent mosquito biting rate, to find the optimal vaccination age against dengue in Brazil with Dengvaxia. The optimal vaccination age and minimal lifetime expected risk of hospitalisation are found by adapting a method due to Hethcote (Math Biosci 89:29-52). Any number and combination of the four dengue serotypes DENv1-4 is considered. Successful vaccination against a serotype corresponds to a silent infection. The effects of antibody-dependent enhancement (ADE) and permanent cross-immunity after two heterologous infectio...
Source: Bulletin of Mathematical Biology - Category: Bioinformatics Authors: Tags: Bull Math Biol Source Type: research
Publication date: Available online 10 January 2020Source: Antiviral ResearchAuthor(s): Elizabeth C. Clarke, Steven B. BradfuteAbstractFor more than 20 years, researchers have used laboratory mice lacking type I or both type I and type II interferon (IFN) responses to study viruses that cause hemorrhagic fever (HF) in humans. Whereas immunocompetent mice do not become ill when infected with Ebola, Lassa, dengue and other HF viruses, IFN-deficient mice typically develop severe or fatal disease when inoculated with these pathogens. The ease of employment of these “mouse models” has led to their extensive use in bi...
Source: Antiviral Therapy - Category: Virology Source Type: research
Abstract For more than 20 years, researchers have used laboratory mice lacking type I or both type I and type II interferon (IFN) responses to study viruses that cause hemorrhagic fever (HF) in humans. Whereas immunocompetent mice do not become ill when infected with Ebola, Lassa, dengue and other HF viruses, IFN-deficient mice typically develop severe or fatal disease when inoculated with these pathogens. The ease of employment of these "mouse models" has led to their extensive use in biocontainment laboratories to assess the efficacy of novel vaccines, often without consideration of whether adaptive im...
Source: Antiviral Research - Category: Virology Authors: Tags: Antiviral Res Source Type: research
PMID: 31909484 [PubMed - as supplied by publisher]
Source: Med J Aust - Category: General Medicine Authors: Tags: Med J Aust Source Type: research
CONCLUSIONS: WHO recommended option of a screen and vaccinate policy is likely to have a positive impact both at the individual and population level across a wide range of transmission settings and has the potential to be as, if not more, cost-effective than a no screening strategy. PMID: 31879126 [PubMed - as supplied by publisher]
Source: Vaccine - Category: Allergy & Immunology Authors: Tags: Vaccine Source Type: research
Future Virology,Volume 14, Issue 10, Page 671-691, October 2019.
Source: Future Virology - Category: Virology Authors: Source Type: research
Publication date: 14–20 December 2019Source: The Lancet, Volume 394, Issue 10215Author(s): Annelies Wilder-Smith, Stefan Flasche, Peter G Smith
Source: The Lancet - Category: General Medicine Source Type: research
More News: Dengue Fever | Genetics | Infectious Diseases | Japan Health | Science | Vaccines